| Association | Year | Country | Recommendation |
| Osteoarthritis Research Society International (OARSI) | 2014 | USA | Uncertain―varying quality of evidence and conflicting results |
| National Institute for Health and Care Excellence (NICE) | 2014 | UK | Do not recommend―uncertainty and varying quality throughout the evidence. Hyaluronic acid is deemed to not be cost-effective |
| Veterans Affairs/Department of Defense (VA/DoD) | 2014 | USA | Uncertain?insufficient evidence available; however, IA-HA may be considered if other treatment options are unsuccessful |
| American Academy of Orthopedic Surgeons (AAOS) | 2013 | USA | Do not recommend―based on a lack of IA-HA efficacy, not potential harm. High variability in the quality of current evidence noted. |
| American College of Rheumatology (ACR) | 2012 | USA | No recommendation made regarding the use of IA-HA for initial knee OA management; however, IA-HA is recommended for patients ≥75 that have not had a satisfactory clinical response to acetaminophen |
| American Academy of Family Physicians (AAFP) | 2012 | USA | Recommended as a consideration for severe knee OA cases when other treatment options have been unsuccessful |
| Royal Australian College of General Practitioners (RACGP) | 2009 | Australia | Grade C recommendation―there is some evidence to suggest that IA-HA is of some benefit for OA of the knee |
| National Collaborating Centre for Chronic Conditions (NCC-CC) | 2008 | UK | Do not recommend―Highly variable evidence regarding IA-HA efficacy, deemed not cost-effective |
| Agency for Healthcare Research and Quality (AHRQ) | 2008 | USA | Uncertain―due to variability in trial quality and unclear significance |
| European League Against Rheumatism (EULAR) | 2003 | France | No recommendation made regarding the use of IA-HA for initial knee OA management; however, an acknowledgement of potential efficacy |